PTGS2 and breast cancer: Two recently published studies evaluated its use in the peri-operative period; one evaluated propranolol at a consistently lower dose along with a cyclooxygenase− 2 inhibitor among breast cancer patients [28] and another assessed propranolol use in ovarian cancer patients [29].